• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar.

作者信息

Kay Jonathan, Dörner Thomas, Emery Paul, Kvien Tore K, Breedveld Ferdinand C

机构信息

Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA

Department of Medicine/Rheumatology and Clinical Immunology, Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum (DRFZ), Berlin, Germany.

出版信息

Ann Rheum Dis. 2020 Apr;79(4):e44. doi: 10.1136/annrheumdis-2018-214994. Epub 2019 Jan 18.

DOI:10.1136/annrheumdis-2018-214994
PMID:30659047
Abstract
摘要

相似文献

1
Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar.临床试验和“真实世界”数据支持从生物原研药转换为其生物类似药。
Ann Rheum Dis. 2020 Apr;79(4):e44. doi: 10.1136/annrheumdis-2018-214994. Epub 2019 Jan 18.
2
Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.开始使用生物类似药英夫利昔单抗的类风湿关节炎患者的特征与结局
Rheumatol Int. 2017 Jun;37(6):1007-1014. doi: 10.1007/s00296-017-3663-z. Epub 2017 Feb 18.
3
Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.从原研英夫利昔单抗转换为其生物类似药CT-P13后的长期随访：无安慰剂效应的影响
Ann Rheum Dis. 2020 Jan;79(1):e11. doi: 10.1136/annrheumdis-2018-214374. Epub 2018 Oct 23.
4
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.英夫利昔单抗和依那西普原研药与相应生物类似药治疗保留率：北欧协作观察性研究 2334 例生物制剂初治的脊柱关节炎患者。
RMD Open. 2019 Oct 23;5(2):e001079. doi: 10.1136/rmdopen-2019-001079. eCollection 2019.
5
Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis.非感染性葡萄膜炎患者从原研英夫利昔单抗转换为英夫利昔单抗-abda 生物类似药后的炎症复发率。
Am J Ophthalmol. 2021 May;225:172-177. doi: 10.1016/j.ajo.2020.08.005. Epub 2020 Aug 12.
6
Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.强制的、成本驱动的从原研药依那西普转换为其生物类似药SB4：对非医学转换可能产生的影响。
Ann Rheum Dis. 2020 Feb;79(2):e13. doi: 10.1136/annrheumdis-2018-214757. Epub 2018 Nov 28.
7
Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB: possible fallout on non-medical switching' by Cantini and Benucci.对坎蒂尼和贝努奇所著《强制、成本驱动下从原研依那西普转换为其生物类似药SB：非医学转换可能产生的影响》的回应
Ann Rheum Dis. 2020 Feb;79(2):e14. doi: 10.1136/annrheumdis-2018-214788. Epub 2018 Dec 20.
8
Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.英国儿童和青少年幼年特发性关节炎患者使用肿瘤坏死因子拮抗剂生物类似药转换后的结局：一项全国性队列研究。
Lancet Rheumatol. 2024 Jul;6(7):e438-e446. doi: 10.1016/S2665-9913(24)00087-0. Epub 2024 Jun 3.
9
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.英夫利昔单抗生物类似药-生物类似药转换治疗炎症性风湿病患者：DANBIO 注册研究中真实世界患者的临床结局。
RMD Open. 2022 Nov;8(2). doi: 10.1136/rmdopen-2022-002560.
10
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.在真实世界中，类风湿关节炎患者起始使用英夫利昔单抗生物类似药IFX-dyyb的特征及6个月结局
Rheumatol Ther. 2024 Jun;11(3):841-853. doi: 10.1007/s40744-024-00653-6. Epub 2024 Mar 20.

引用本文的文献

1
Regulatory Framework for Supporting the Integration and Use of Biosimilars in the Private Healthcare System of the United Arab Emirates (UAE).支持生物类似药在阿拉伯联合酋长国（阿联酋）私立医疗系统中整合与使用的监管框架。
Cureus. 2024 Nov 27;16(11):e74581. doi: 10.7759/cureus.74581. eCollection 2024 Nov.
2
Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting.生物制品的初始处方和药物转换：瑞士医疗保健环境下处方途径和决定因素的分析。
BMJ Open. 2023 Nov 21;13(11):e077454. doi: 10.1136/bmjopen-2023-077454.
3
Maximizing the benefits of using biosimilars in Egypt.
在埃及实现生物类似药使用效益的最大化。
J Pharm Policy Pract. 2023 Jun 26;16(1):79. doi: 10.1186/s40545-023-00581-w.
4
Real-world use of an etanercept biosimilar including selective automatic substitution in inflammatory arthritis patients: a UK-based electronic health records study.英夫利昔单抗生物类似药在现实世界中的应用，包括在炎性关节炎患者中的选择性自动替换：一项基于英国电子健康记录的研究。
Rheumatol Adv Pract. 2022 Jul 27;6(2):rkac056. doi: 10.1093/rap/rkac056. eCollection 2022.
5
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?生物类似药与生物类似药的转换：其原理和当前经验是什么？
Drugs. 2021 Nov;81(16):1859-1879. doi: 10.1007/s40265-021-01610-1. Epub 2021 Oct 27.
6
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.英夫利昔单抗和依那西普原研药与相应生物类似药治疗保留率：北欧协作观察性研究 2334 例生物制剂初治的脊柱关节炎患者。
RMD Open. 2019 Oct 23;5(2):e001079. doi: 10.1136/rmdopen-2019-001079. eCollection 2019.
7
Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.从原研药到生物类似药依那西普的强制性非医学转换是否会导致炎症性关节炎患者的医疗保健使用和成本增加？一项丹麦基于登记的研究。
RMD Open. 2019 Aug 12;5(2):e001016. doi: 10.1136/rmdopen-2019-001016. eCollection 2019.